Blog

BlogApril 21, 2022

PRO: A Deeper Dive Into ATAI’s Strategic Partnership With IntelGenX

BlogApril 15, 2022

PRO: A Deeper Dive Into The Numinus + Novamind Merger

BlogApril 8, 2022

PRO: Comparing The Largest Psychedelic Companies Post Earnings

BlogApril 4, 2022

Multiple Psychedelics Companies Come Together In a Watershed Moment For Psilocybin Therapy

BlogApril 1, 2022

PRO: Rapid Reactions To ATAI’s 2021 Year-End Financial Results

BlogMarch 29, 2022

PRO: Rapid Reactions To Mind Medicine’s 2021 Year-End Financial Results

BlogMarch 18, 2022

PRO: Companies Focused on DMT

BlogMarch 17, 2022

What’s Going On with MINDCURE?

BlogMarch 11, 2022

PRO: A Deeper Dive Into Seelos Therapeutics

BlogMarch 3, 2022

A Deeper Dive Into Novamind’s Q2 Financial Results

BlogMarch 3, 2022

The Scientific Community is Investing Heavily in “The God Molecule”

BlogFebruary 14, 2022

Psychedelic Invest PRO Video: Weekly Content Teaser

BlogFebruary 11, 2022

Psychedelics in 2022: Iter Investments and Industry Predictions

BlogJanuary 26, 2022

Video: The Psychedelics Industry in 2021

BlogJanuary 18, 2022

Over $730M Was Invested in Psychedelics in 2021

BlogJanuary 7, 2022

Numinus To Follow TSX Upgrade with US Listing in 2022 – CEO

BlogJanuary 7, 2022

Is This the End of Patents on Psilocybin?

BlogDecember 31, 2021

2021: The Year in Psychedelics

BlogDecember 10, 2021

A New Cross-Sector Partnership Means a Huge Step Forward for MDMA Therapy

BlogDecember 10, 2021

How to Effectively Market Your Psychedelic Brand

BlogNovember 17, 2021

What Happened Last Week with the Market?: A Look at Compass Pathways and Clinical Results

BlogNovember 16, 2021

Finding Value in the Clinical Space: A Conversation with Iter Investments Founder Dustin Robinson

BlogMay 2, 2021

Creating a Sustainable Psychedelics Ecosystem

BlogSeptember 3, 2020

Better Plant Sciences Announces OTC Ticker Symbol Change to “VEGGF”